Aldeyra Therapeutics (ALDX) Shares Outstanding (2013 - 2026)

Aldeyra Therapeutics (ALDX) has 14 years of Shares Outstanding (Entity) data on file, last reported at $60.3 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) changed 0.46% year-over-year to $60.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.3 million (changed 0.46% YoY) and the FY2025 annual result came in at $60.2 million, up 0.86% from the prior year.
• Shares Outstanding (Entity) steadied at $60.3 million in Q1 2026, from $60.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $60.3 million in Q1 2026 to a low of $58.3 million in Q1 2022.
• A 5-year average of $59.3 million and a median of $59.4 million in 2024 frame the typical range for Shares Outstanding (Entity).
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 22.35% — and 2026, when it gained 0.46%.
• Tracing ALDX's Shares Outstanding (Entity) over 5 years: stood at $58.6 million in 2022, then advanced by 1.09% to $59.2 million in 2023, then gained by 0.76% to $59.6 million in 2024, then rose by 0.86% to $60.2 million in 2025, then rose by 0.26% to $60.3 million in 2026.
• The last three Shares Outstanding (Entity) figures came in at $60.3 million (Q1 2026), $60.2 million (Q4 2025), and $60.2 million (Q3 2025), per Business Quant data.